Login
Contact

Explore

Explore

About
  • People and Partners
  • TRI Building
  • Reconciliation Action Plan
  • Strategic Plan
  • TRI Foundation
  • Careers
Research
  • Collaborate
  • Discovery
  • Translate
  • Engage
  • Research Areas
Clinical
  • Translational Trials
  • Clinical Research Facility
  • TRI at Children’s
Industry
  • TRI Incubator
  • The Precinct
  • Residents
Manufacture
  • New cGMP Facility
Facilities
  • Cleanroom
  • Flow Cytometry
  • Histology
  • Microscopy
  • Proteomics
  • Preclinical Imaging
  • Biological Research
  • Gnotobiotics
  • Human Immune Model
Get Involved
  • Health Consumers
  • SPARQ-ed
Resources
  • News
  • Events
  • Case Studies
  • Grants and Funding
  • Education and Training

+61 7 3443 7000info@tri.edu.au37 Kent Street, Woolloongabba QLD 4102 Australia

Acknowledgement of Country

TRI acknowledges the traditional custodians of the land we are on today, the Turrbal and Jagera people and we recognise their continuing connection to land, waters and community. We pay deep respect to them and their cultures; and to Elders past, present and emerging.

© Translational Research Institute Pty Ltd atf the Translational Research Institute Trust|ABN: 58 155 991 662
Privacy policy|Terms of Use|Contact Us
TRI · TM@TRI · New cGMP Facility

New cGMP Facility

ManufactureNew cGMP Facility

Tour the Facility due to open 2026

An Australian First

Australia’s first scale-up multi-product biomedical cGMP cleanroom facility on demand, for maturing, high-potential, med-tech and biotech start-ups.

Our operating model sees us working as a trusted partner and facilitator, supporting our tenants on their research and development and manufacturing journeys.

By basing your business at TM@TRI, you get access to a state-of-the-art compliant cGMP facility, while maintaining control over your manufacturing process and IP.

Services Provided

This facility is designed to reduce the barrier to entry for start-ups by providing compliant and flexible cGMP facilities on demand, wrap-around cGMP compliance services, and expert technical support.

Dedicated facility management

Qualified Enterprise Resource Planning system (ERP)

 

cGMP systems framework, technical expertise and support

Quality Management System (QMS)

Wrap-around compliance support available

Flexibility offering full control over manufacturing

Supply chain and logistical support

Temperature controlled storage

What will this mean for biomedical research?

From incubation to clinical trials and manufacture, TRI’s new translational manufacturing facility will be a catalyst for advancing innovation here in Australia.

Learn more.

What will this mean for biomedical research?

From incubation to clinical trials and manufacture, TRI’s new translational manufacturing facility will be a catalyst for advancing innovation here in Australia.

Learn more.

What will this mean for biomedical research?

From incubation to clinical trials and manufacture, TRI’s new translational manufacturing facility will be a catalyst for advancing innovation here in Australia.

Learn more.

What will this mean for biomedical research?

From incubation to clinical trials and manufacture, TRI’s new translational manufacturing facility will be a catalyst for advancing innovation here in Australia.

Learn more.

Scale-up biomedical manufacturing capability

  • cGMP qualified facilities
  • 5x commissioned, qualified and segregated cleanrooms
  • Up to ISO 7 (Grade B) capable cleanrooms
  • Qualified utilities and 24/7 critical systems monitoring by BMS
  • Continuous particle monitoring (fully qualified, 21 CFR part 11 and PIC/S – Annex 11 – compliant) EMS
  • PC2 regulatory compliant laboratories
  • Co-working desk spaces and offices, including meeting rooms and pitch spaces
  • Innovation space to support engineering and chemistry (non GMP space)
  • Access to all TRI facilities, services and support including dedicated clinical trial facilities

“It is our intention to ensure our tenants are provided appropriate wraparound services so they are well equipped and supported to have the best possible route towards manufacturing and translational outcomes for their products and innovation.”

David Crowley

General Manager, Translational Biomedical Manufacturing

Is your business a good fit?

TM@TRI is not a CDMO, requiring tenants to meet facility fit criteria and remain responsible for manufacturing processes, regulatory licensing and compliance.

Start-up companies nearing clinical manufacturing

Companies in R&D phases manufacturing product for Clinical Trial are ideally suited to the TM@TRI model.

Organisations requiring cGMP cleanroom access

TM@TRI will house tenants with a specific requirement for cGMP cleanroom access.

Biologics/ Therapeutic sector – Phase 1 (Australia)

Designed to partner with tenants through scale up, technology transfer and execution.

Medical technologies and diagnostics companies

Ideally suited to companies who are still at developmental stage, working in human health.

Chemistry and engineering innovation space requirement

Delivering innovation and collaboration spaces purpose-designed for non-cGMP uses.

Enter your details to register your interest and dowload an information pack.